Tesla, Inc. vs Zoetis Inc — how do they compare? Tesla, Inc. trades at $379.31 (market cap $1.39T), while Zoetis Inc trades at $76.07 (market cap $31.95B). The key difference: Tesla, Inc. is far larger — about 43.5× Zoetis Inc's market cap, and Zoetis Inc pays a 2.78% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| TSLA | ZTS | |
|---|---|---|
Market Cap | $1.39T | $31.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $489.88 | $156.76 |
52-Week Low | $302.63 | $71.91 |
Enterprise Value | $1.36T | $39.24B |
Dividend Yield | — | 2.78% |
Signals from Pluang's Aura AI — not financial advice
Tesla (TSLA) trades at $378.88, down 0.51% on the day, as the stock faces technical bearish signals despite recent earnings beats. The company shows mixed fundamentals with revenue declining to $94.83B in 2025 and net income margin compressing to 3.95%, while valuation multiples remain elevated with a P/E of 339.06. Recent news highlights Tesla's strategic pivot toward robotics, AI, and energy growth amid a slowing auto business, with regulatory approval for driver-assistance software in Europe providing a potential catalyst.
Tesla's investment case balances high-growth potential in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $409.26 suggests modest upside, but investors face headwinds from competitive pressures and margin compression. The stock's trajectory will likely hinge on successful commercialization of new technologies and improved automotive profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →